

# French National Plans against hepatitis B and C ... and the way forward

Françoise Roudot-Thoraval  
Department of Public Health  
Hôpital Henri Mondor –  
Université Paris Est Créteil

# HCV/HBV studies and responses :Timeline

1st national sero-prevalence survey

Episodes of transmission in health-care settings

High prevalence in DUs

Conference on Hep C treatment

• National seroprevalence survey in DUs

• 2<sup>nd</sup> national sero-prevalence survey + HBV

Surveillance

1994

1996

1999

2002

2004

2009

Implementation of hepatology reference centres

1st national Plan (HCV)

2nd national Plan(HCV+HBV)

Law relative to public health policy

3rd national Plan (HCV+HBV)

# Stakeholders of the Plan



# The French National Plan 2009-2012

1. Reduction of HBV and HCV transmission, and increase of HBV immunization  
4 objectives – 17 actions
2. Stepping up hepatitis B and C identification  
2 objectives – 6 actions
3. Improvement of access to care and quality of life of patients  
4 objectives – 11 actions
4. Special measures adapted to prison milieu  
1 objective – 5 actions
5. surveillance and evaluation, research forecasting  
4 objectives – 16 actions


# Objectives of the national plan

1. Reduction of HBV and HCV transmission
  - Intensify information and communication about hepatitis
  - **Increase HBV vaccine coverage**
  - reinforce harm reduction in IVDU
  - Improve risk prevention in care settings
2. Stepping up hepatitis B and C screening
  - Set up the conditions of a better access to screening of people at risk
  - Improve the practice of testing and counselling
3. Improvement of access to care and quality of life of patients
  - **Improve management of HCV treatment**
  - **Encourage therapeutic education**
  - Support actions in collaboration with reference centers, patients associations
4. Special measures adapted to prison milieu
  - concerning harm reduction programmes, screening and access to treatment
5. Surveillance and evaluation – research forecasting
  - Improve surveillance and epidemiological knowledge
  - **Develop research and forecasting**
  - Follow-up and evaluation of the national plan

# What has been done ?

- Prevention
- Screening
- Treatment
- Research

# HBV prevention: Rate of HBV coverage in infants



# Screening – link to care

- High activity of screening
  - 3.4 millions HCV Elisa tests per year
    - Incidence of new diagnoses: 1/10 000 to 1/1 000 according to the region ????repeated tests
  - 3.4 millions HBs Ag tests per year
    - Incidence of new diagnoses: 1/10 000 to 1/1 000 according to the region ???? Repeated tests

- Proportion aware of their infection

	1994	2004	2014
HCV	24%	56%	65% (modelling)
HBV		46%	



# Screening – link to care

- HCV

Infected patients (2004) 240 000

Naïve treated patients (up to 2014) 70 000

Cured patients 35 000

(dead 15 000)

Residual infected patients 190 000

Screened	To be screened
120 000	70 000


– Proposal : to treat 15 000 patients per year with DAAs

– (14 000 have been treated in 2014)

# Research

- Epidemiological
  - Modeling HCV epidemiology
  - Cost-effectiveness studies
- Therapeutic
  - Study « CUPIC »
  - Cohort « HEPATHER »
    - More than 2000 patients included and treated with new DAAs to study efficacy and safety in real life


# Impact of new treatments on HCV epidemiology in France



Prevalence: - 68.000  
Mortality avoided: 8100  
Cirrhoses avoided: 8200

# Research


- Epidemiological
  - Modeling HCV epidemiology
  - Cost-effectiveness studies
- Therapeutic
  - Study « CUPIC »
  - Cohort « HEPATHER »
    - More than 2000 patients included and treated with new DAAs to study efficacy and safety in the real life



# The way forward

- Guidelines for the management of patients with HBV or HCV
  - Report = « state of the art » in 2013-14
  - Guidelines and recommendations (180)
  - Creation of a follow-up committee
    - In charge of prioritization of actions
    - Think at implementation strategies for their achievement
    - Follow-up of actions
  - Opportunity to achieve, at least improve what remains to do for the prevention and control of hepatitis in France

# Impact of new treatments on HCV epidemiology in France



Prevalence: - 68.000  
Mortality avoided: 8100  
Cirrhoses avoided: 8200



*Thank you for your attention*